Shares of Fortress Biotech (formerly known as Coronado Biosciences) surged after the company announced that a glioblastoma patient who showed no response to standard of care treatments had a remarkable turnaround after being treated with the company’s Phase I drug candidate, MB-101.
For the second time in less than a year, Provectus Biopharmaceuticals Inc. is down a chief executive officer.
Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition.
A federal appeals court revived a lawsuit accusing Medtronic Plc of defrauding shareholders by covering up negative side effects from its Infuse bone growth product for nearly a decade.
Tedor Pharmaceuticals is expanding its Rhode Island manufacturing facility and expanding its employment with more than 20 new positions, the company announced.
After suffering a setback in 2016, Regeneron could be poised for a turnaround in 2017 and it hinges on correcting manufacturing problems that caused regulators to block approval of a new drug to treat rheumatoid arthritis.
A Harvard professor has retracted research that was once considered a breakthrough in diabetes research.
The serial testing of some volunteers is raising new questions about the level of oversight of India’s generic drug trials industry, after some CROs came under recent international regulatory scrutiny.
Anthera Pharmaceuticals Inc. said its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company’s shares tumbling nearly 70 percent in after-hours trading.
The U.S. government issued rules for addressing cyber vulnerabilities in medical devices, providing manufacturers with guidelines for fixing security bugs in equipment, including pacemakers, insulin pumps and imaging systems.